The Migraine and Pain Study GeneBank at Scripps Clinic Registry (MAPS)
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 61
- Locations
- 1
- Primary Endpoint
- Gene identification
Study Overview
Brief Summary
The objective of this study is to obtain blood or saliva samples to define genes for migraine and pain diseases.
Detailed Description
It is estimated that over one-third of the world's population suffers from persistent or recurrent pain. Migraine is highly heritable and the majority of juveniles who suffer from the disorder have a mother or father who also have the disease. The blood or saliva samples will go through DNA analysis and be sequenced for candidate genes or subjected to whole-genome sequencing. By creating a MAPS GeneBank from these patients' blood/saliva donations we will ultimately be able to define genes for migraine and pain diseases.
Study Design
- Study Type
- Observational
- Observational Model
- Family Based
Eligibility Criteria
- Ages
- 10 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Family members (genetic duo or trio), consisting of an adolescent 10 to 18 years of age and at least one of their biologic parents willing to be participate in trial
- •Adolescent and at least 1 biologic parent with Migraine diagnosis confirmed by Dr. Christy Jackson
- •Is reliable, cooperative and willing to comply with all protocol-specified procedures and/or sub-study if consented
- •Able to understand and grant informed consent
Exclusion Criteria
- •Patient has been previously enrolled in the MAP GeneBank at Scripps Clinic Registry
- •Has a significant chronic medical condition (i.e.chronic meningitis or a secondary origin/cause of headache) which, in the investigator's option, may interfere with the patient's optimal participation in the study
- •Treatment with any investigational agents or devices within 30 days preceding enrollment in the study
- •Has undergone ECT within 90 days preceding enrollment in the study
Outcomes
Primary Outcomes
Gene identification
Time Frame: end of study
By creating a MAPS GeneBank from these patients' blood/saliva donations we will ultimately be able to define genes for migraine and pain diseases.
Secondary Outcomes
No secondary outcomes reported
Investigators
Eric Topol, MD
Director, Scripps Translational Science Institute
Scripps Translational Science Institute